Valued at USD 9.05 billion in 2024, the global non-Hodgkin lymphoma (NHL) therapeutics market is anticipated to grow at a CAGR of 7.7% from 2025 to 2034. This growth is being driven by significant advancements across key therapeutic segments, including monoclonal antibodies, immunomodulatory agents, chemotherapy drugs, and cell and gene therapies. As the treatment paradigm shifts toward targeted and personalized therapies, market participants are increasingly focusing on product differentiation and value chain optimization to capture segment-wise performance and sustain competitive advantage.
Monoclonal antibodies (mAbs),